| Michael Warhit, MD | |
|
201 Lyons Ave, Newark, NJ 07112-2027 | |
| (973) 926-7960 | |
| Not Available |
| Full Name | Michael Warhit |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 10 Years |
| Location | 201 Lyons Ave, Newark, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063821726 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | 283987 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Englewood Hospital And Medical Center | Englewood, NJ | Hospital |
| Chilton Medical Center | Pompton plains, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Newton Imaging P.a. | 1254325970 | 43 |
| Valley Physician Services Pc | 3577857333 | 402 |
| Hudson Premier Medical Pc | 4688095367 | 16 |
| Ancillary Services Of Practice Associates Pa | 4981026192 | 62 |
| Englewood Radiologic Group P A | 6901852300 | 33 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Edison Radiology Group Pa Jfk Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417013731 PECOS PAC ID: 1052209699 Enrollment ID: O20040305001072 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Newton Imaging P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1417988841 PECOS PAC ID: 1254325970 Enrollment ID: O20040414000293 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Robert Wood Johnson Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1902848625 PECOS PAC ID: 8628065117 Enrollment ID: O20040427001205 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Montclair Radiological Assoc Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194810531 PECOS PAC ID: 3274507447 Enrollment ID: O20040824000016 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Englewood Radiologic Group P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639136914 PECOS PAC ID: 6901852300 Enrollment ID: O20050329000957 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Nbimc Department Of Radiology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1831236769 PECOS PAC ID: 5193821874 Enrollment ID: O20070427000034 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Valley Physician Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467815928 PECOS PAC ID: 3577857333 Enrollment ID: O20160802002824 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Hudson Premier Medical Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548809221 PECOS PAC ID: 4688095367 Enrollment ID: O20200604002360 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Ancillary Services Of Practice Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144858408 PECOS PAC ID: 4981026192 Enrollment ID: O20200617000058 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Rwjbh Observation Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760095806 PECOS PAC ID: 5193137503 Enrollment ID: O20201209000008 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Entity Name | Eoh Acquisition Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1578922258 PECOS PAC ID: 4082009717 Enrollment ID: O20220317002585 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Warhit, MD 843 Keene Ln, Woodmere, NY 11598-2216 Ph: (516) 297-8266 | Michael Warhit, MD 201 Lyons Ave, Newark, NJ 07112-2027 Ph: (973) 926-7960 |
News Archive
Cell Therapeutics, Inc. (CTI) and Chroma Therapeutics Ltd. announced today that Lancet Oncology has published results from the OPAL Phase 2 study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML).
A study published on May 17 in Nature, discovers an innovative method to produce infinite supply of healthy blood cells from the readily available cells that line blood vessels. This achievement by the researchers at Weill Cornell Medicine marks the first time that any research group has generated such blood-forming stem cells.
Although the vast majority of pediatric spine surgeries are safe, a handful of neuromuscular conditions seem to fuel the risk of cardiac arrest during such operations, according to research led by investigators at the Johns Hopkins Children's Center.
Cell Therapeutics, Inc. (CTI) has announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.
› Verified 4 days ago
Dr. Keith Michael Spellman, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 201 Lyons Ave, Newark, NJ 07112 Phone: 973-926-7960 | |
Kris Arun Nathan, DO Radiology Medicare: Medicare Enrolled Practice Location: 201 Lyons Ave, Newark, NJ 07112 Phone: 973-926-7000 | |
Dr. Omar Jamil, MD Radiology Medicare: Medicare Enrolled Practice Location: 185 S Orange Ave, Department Of Surgery, Medical Science Building, G-506, Newark, NJ 07103 Phone: 973-972-6639 | |
Dr. Candido P Quinones, MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 111 Central Ave, Newark, NJ 07102 Phone: 973-877-5287 | |
John Yoon, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 201 Lyons Ave Dept Of, Newark, NJ 07112 Phone: 732-763-0437 | |
Debra J. Green, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 30 Bergen St, Admc 12 1205, Newark, NJ 07107 Phone: 973-972-0037 Fax: 973-972-9355 |